Tirzepatide (TIRZ)

Metabolic FDA approved

Dual GIP/GLP-1 receptor agonist showing superior weight loss compared to GLP-1 agonists alone. Brand names include Mounjaro and Zepbound.

Key Data

Research Status
FDA approved
Half-Life
~5 days
Administration
Subcutaneous injection
Typical Dosage
2.5-15 mg weekly

Mechanism of Action

Activates both GIP and GLP-1 receptors for enhanced metabolic effects and greater weight loss.

Reported Benefits

All information is presented for Research Use Only (RUO). Not medical advice.

← All Peptides Dosing Calculator Community Forum Home